+91-8668442535

Usher Syndrome Market By Type (Type 1, Type 2, Type 3, Others) By Diagnosis (Electroretinogram, Optical Coherence Tomography, Videonystagmography, Audiology, Genetic Testing, Others) By Treatment (Devices, Drugs, Therapy, Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) By End User (Hospitals, Home-care, Specialty Clinics, Others)- Growth, Share, Opportunities & Competitive Analysis, 2016 – 2028

What are the diagnosis and treatment options commonly available in Usher Syndrome?

Usher syndrome is a rare hereditary illness that is characterised by deafness as well as retinitis pigmentosa. The inner ear and auditory nerves' ability to carry sound to the brain is impaired in this condition, resulting in deafness. Retinitis pigmentosa is a condition that affects the retina and causes visual loss over time. Usher syndrome can be classified into three main clinical categories. The syndrome is passed down through the generations as an autosomal recessive genetic characteristic. Deafness is one of the symptoms of Usher Syndrome, which is caused by a disturbance in signal transmission between the auditory nerves, the inner ear, and the brain. Furthermore, pigmented material accumulates on the retina, resulting in gradual vision lose and legal blindness. One of the major factors driving the growth of the usher syndrome market is the increase in the number of people suffering from it around the world.

Usher syndrome affects 4 to 17 people per 100,0001,2 and accounts for nearly half of all occurrences of hereditary deaf-blindness. The syndrome is thought to affect 3 to 6 % of all deaf children and another 3 to 6 % of hard-of-hearing youngsters. Studies have also demonstrated that even with a reduction in peripheral vision, clear central vision can be preserved for many years. Some symptoms are type-specific, like as balance problems in patients with Type 1 and 3 Usher syndrome. Balance, vision, and hearing tests are used to determine whether or not someone has Usher syndrome. Genetic testing is also carried out to determine which genes are linked to the condition. Usher Syndrome is now treated with symptomatic and supportive care. Cochlear implants or hearing aids are extremely effective for newborns and children with hearing loss. There is no current treatment for retinitis pigmentosa; low-vision devices are provided instead.

What is the Market Size of Usher Syndrome in terms of value?

The global Usher Syndrome Market is projected to increase at a significant CAGR of  3.58% in the coming years. In 2021, the global Usher Syndrome market was valued at USD 147.15 million and is projected to reach at the value of USD 195.37 million by 2028. The demand for Usher Syndrome is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD 1,250 million during the forecast period of 2022 and 2028.

usher-syndrome-market.img1

What is the key emerging drugs for Usher Syndrome?

QR-421a: ProQR Therapeutics

QR-421a is an experimental RNA therapy aimed at preventing vision loss in persons with retinitis pigmentosa (RP) and Usher syndrome caused by mutations in exon 13 of the USH2A gene. QR-421a works by binding to the mutant USH2A RNA and preventing exon 13 from being included in the RNA. Exon skipping is the term for this method. The retinal cells can then synthesise a somewhat shorter but functional version of USH2A. Stellar is a global clinical trial of QR-421a in people with Usher syndrome and retinitis pigmentosa (RP) caused by mutations in the USH2A gene's exon 13.

NPI-001: Nacuity Pharmaceuticals

NPI-001 is a medication that is currently in phase 1/l1 of development for the treatment of Retinitis Pigmentosa in Usher sufferers. The product has been designated as an orphan medication, which may provide regulatory exclusivity to the company.

Interesting Facts about Usher Syndrome Industry

  • A key driving force in the worldwide usher syndrome market is the global epidemic of genetic and hereditary illnesses. Many people are opting for better operations, minimally invasive surgeries, and higher disease awareness, all of which could benefit the usher syndrome industry. Increased investment, R&D activity in the field of genetic and hereditary illnesses, and population expansion all benefit the industry.
  • North America region had a major share in terms of volume as well as value in the global Usher Syndrome market in 2021 and is projected to continue its dominance over the forecast period.
  • There are approximately 4+ major firms working on therapeutics for Usher Syndrome. ProQR Therapeutics and others are among the companies with Usher Syndrome drug candidates in the mid to advanced stages, i.e. Phase Ill and Phase Il.
  • Companies and academics are collaborating to examine difficulties and identify possibilities that could impact Usher Syndrome research and development. Novel techniques to treating/improving Usher Syndrome are the focus of the medicines in development.

Who are the Top 10 players/companies in the Usher Syndrome market in term of value?

The key players in the global Usher Syndrome market in terms of value include Amgen, Inc., Century Hearing Aids, MeiraGTx, Zounds Hearing and Sivantos Pte. Ltd., Nobelpharma Co., Ltd., Advanced Bionics AG, Editas Medicine, Inc., ProQR Therapeutics NV Sanofi Corporation, Cochlear Ltd. and Johnson & Johnson Services, Inc.. These key players are concentrating on new product developments as well as technological innovation to enhance their production in Usher Syndrome to gain competitive market share at a global level. For instance, in December 2020,, The FDA granted orphan drug status for the treatment of retinitis pigmentosa, a condition that frequently affects people with Usher syndrome. The FDA has granted a new cell therapy that can chemically convert cells into photoreceptor-like cells special status. These photoreceptor-like cells aid in the partial recovery of visual function and the pupil reflex. On the other hand, Eyevensys S.A.S., a biotechnology company, has been granted orphan drug status by the FDA for EYS611, a treatment for retinitis pigmentosa. Eyevensys has been granted a seven-year exclusivity period for EYS611.

Who are the Top 10 Countries in the Usher Syndrome Market?

In the global Usher Syndrome market, the major countries are US, China, Japan, India, South Korea, Germany, France, UK, Brazil and Africa. The largest market share is in United States. According to a report provided by the United States Department of Health and Human Services, Usher syndrome affects roughly 4-17 people per 100,000 people and accounts for 50 % of all occurrences of hereditary deaf-blindness. The availability of refined healthcare infrastructure and advancements in audiology aids are the primary drivers driving market expansion. Usher syndrome types 1 and 2 are the most common in most countries. Usher syndrome affects approximately one in every 23,000 people in the United States and its suburbs, with a type 1 to type 2 ratio of one to three. During the projected period, the Usher syndrome market is expected to rise at a rapid pace. This is due to an increase in the prevalence of hereditary diseases.

There is a trend toward improvised operations, minimally invasive surgeries, and more knowledge of the disease among many individuals, all of which may have a favourable impact on the usher syndrome market. Furthermore, the market benefits from increased investment, increased R&D efforts in the field of genetic and inherited illnesses, and an increase in population. For instance, a United States based biotech company, LambdaVision, Inc., is preparing to debut its artificial retina technology with Space Tango as its engineering partner. Lambdavision's research is looking into the benefits of microgravity in the creation of its artificial retina. Similarly, a clinical-stage company, Ocugen, Inc. (U.S.), investigated the efficacy of an unique modifier gene therapy. In the early stages of retinitis pigmentosa, this treatment produces therapeutic effects.

Which is the Key type segment in the Usher Syndrome Market?

Usher syndrome type 2 is distinguished by birth hearing loss and progressive vision loss that begins in adolescence or adulthood. This type of Usher syndrome causes mild to severe hearing loss that primarily affects the ability to hear high-frequency sounds. Affected people, for example, have difficulty hearing high, soft speech sounds like the letters d and t. The severity of hearing loss varies within and between families with this condition, and it may worsen over time. Type 2 Usher syndrome, unlike the other forms, is not associated with vestibular abnormalities that cause balance problems. The growing number of people suffering from Usher syndrome type 2 drives the global market. The high demand for treatments such as Cochlear Implants, Hearing Aids, and Vitamin A, as well as special designation from regulatory authorities to expedite approval, drive market growth. Continuous advancements in cochlear implantation and hearing kits, as well as substantial financial support for researchers developing novel interventions, all have an impact on the market.

What are the Major Driving Factors for Usher Syndrome Market?

The global epidemic of genetic and inherited disorders is a major driving force in the global usher syndrome market. There is a trend among many people toward improved surgeries, minimally invasive surgeries, and increased disease awareness, which may have a positive impact on the usher syndrome market. Furthermore, increased investment, R&D activities in the field of genetic and inherited disorders, and population growth all have a positive impact on the market. Hearing aids and cochlear implants, both of which can improve hearing, are driving market growth. One of the major factors driving the growth of the usher syndrome market is the increase in the number of people suffering from it around the world. The high demand for treatments such as Cochlear Implants, Hearing Aids, and Vitamin A, as well as special designation from regulatory authorities to expedite approval, drive market growth. Continuous advancements in cochlear implantation and hearing kits, as well as substantial financial support for researchers developing novel interventions, all have an impact on the market.

What are the Major Restraints for Usher Syndrome Market?

In many developing countries around the world, a lack of awareness and disease aetiology stifles market growth. Furthermore, low healthcare budgets in some countries, as well as the inaccessibility and unaffordability of cochlear implants to many underserved people, act as limiting factors in the Usher syndrome market. People's lack of awareness also impedes the market's growth for usher syndrome. Furthermore, the market for usher syndrome is constrained by a lack of proper medical attention in developing countries.

Which Region Dominated the World Usher Syndrome Market?

In 2021, North America is expected to dominate the Usher syndrome market over the forecast period due to the highest R&D and healthcare expenditures, the presence of advanced technology, the growing paediatric population, and the increasing initiatives taken by pharmaceutical organisations to generate novel formulations. Many people are moving toward better surgeries, minimally invasive surgeries, and increased disease awareness, which may benefit the usher syndrome market. Additionally, increased investment, research and development activities in the field of genetic and inherited disorders, and population growth all have a positive impact on the market. Hearing aids and cochlear implants, both of which can improve hearing, are propelling the market forward. The increase in the number of people suffering from usher syndrome around the world is one of the major factors driving the market's growth. For instance, Usher syndrome affects 4 to 17 people per 100,000 people1,2 and accounts for roughly half of all hereditary deaf-blindness cases. The condition is thought to account for 3 to 6 % of all deaf children and another 3 to 6 % of hard-of-hearing children.

Asia Pacific is predicted to account for the greatest market share in the next years for the usher syndrome market due to increased steps taken by the government and pharmaceutical organisations to disseminate awareness and the existence of generic manufacturers. Market growth is fuelled by increased demand for therapies including Cochlear Implants, Hearing Aids, and Vitamin A, as well as special designation from regulatory bodies to accelerate clearance. Continuous improvements in cochlear implantation and hearing aids, as well as significant financial support for researchers creating novel solutions, all have an impact on the market.

Segmentation of Global Usher Syndrome Market-

Global Usher Syndrome Market – By Type

  • Type 1
  • Type 2
  • Type 3
  • Others

Global Usher Syndrome Market – By Diagnosis

  • Electroretinogram
  • Optical Coherence Tomography
  • Videonystagmography
  • Audiology
  • Genetic Testing
  • Others

Global Usher Syndrome Market – By Treatment

  • Devices
  • Drugs
  • Therapy
  • Others

Global Usher Syndrome Market – By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Global Usher Syndrome Market – By End User

  • Hospitals
  • Home-care
  • Specialty Clinics
  • Others

Frequently asked questions about the global Usher Syndrome market

The global Usher Syndrome market is expected to be impacted significantly by COVID-19.

North America accounted for the highest share in the global Usher Syndrome market in terms of value.

The global epidemic of genetic and inherited disorders is a major driving force in the global usher syndrome market. Many people are moving toward better surgeries, minimally invasive surgeries, and increased disease awareness, which may have a positive impact on the usher syndrome market.

Type 2 had a major share in 2021 with more than 35% of the market revenue share.

Hospital Pharmacies segment had a major share in 2021 with more than 45% of the market revenue share.

Usher Syndrome Market Scope

Report Attribute Details
Market Value in 2021 USD 147.15 million
Market Value in 2028 USD 195.37 million
CAGR 3.58%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2022
Category:  Pharmaceuticals
Report ID:   60586
Report Format:   PDF
Pages:   190
Rating:    4.9 (16)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support